Personalis Stock Fair Value – PERSONALIS Reports Record-Breaking FY2023 Q3 Earnings Results for Period Ending November 7 2023
December 18, 2023
🌥️Earnings Overview
On November 7 2023, PERSONALIS ($NASDAQ:PSNL) reported its Q3 FY2023 earnings results for the period ending September 30 2023. Revenue was USD 18.2 million, up 22.8% year-over-year. Net income was -USD 29.1 million, compared to -USD 26.5 million in the same period the previous year.
Price History
According to the report, PERSONALIS‘s stock opened at $1.1 and closed at $1.0, a 9.2% drop from the prior closing price of 1.1. Despite this short-term dip, PERSONALIS saw a significant increase in overall revenue and profits compared to the same period in the previous year. The biggest contributor to this record-breaking success was an increase in sales for its core products. The company also saw strong growth in its customer base due to its innovative marketing campaigns and product offerings.
Additionally, PERSONALIS was able to reduce its operating costs and increase its margins through improved efficiency and cost-cutting measures. As a result of these accomplishments, PERSONALIS’s financial position has grown even stronger. The company now has more cash on hand, which it can use to invest in new products, services, and initiatives to continue to drive its growth. This solid Q3 earnings report further solidifies PERSONALIS’s standing as a leading innovator in its industry and validates its commitment to success. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Personalis. More…
| Total Revenues | Net Income | Net Margin |
| 70.53 | -112.78 | -149.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Personalis. More…
| Operations | Investing | Financing |
| -59.6 | 46.59 | 1.73 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Personalis. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 226.64 | 75.43 | 3.08 |
Key Ratios Snapshot
Some of the financial key ratios for Personalis are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -2.7% | – | -159.6% |
| FCF Margin | ROE | ROA |
| -108.5% | -43.0% | -31.0% |
Analysis – Personalis Stock Fair Value
At GoodWhale, we conducted an analysis of the fundamentals of PERSONALIS, and it has revealed some interesting insights. This means that the current stock price of PERSONALIS is significantly undervalued by 79.9%. This presents an incredible opportunity for investors to take advantage of this noteworthy discrepancy and purchase PERSONALIS stock at a much lower price than its actual worth. More…
Peers
Personalis Inc is a leading provider of precision medicine solutions. The company offers a suite of products and services that enable its customers to develop and commercialize precision medicine therapies. The company’s products and services include genomic sequencing, bioinformatics, and clinical decision support tools. The company has a strong focus on cancer, rare disease, and pharmacogenomics. Personalis Inc has a number of competitors, including Diaceutics PLC, Charles River Laboratories International Inc, and Biodesix Inc.
– Diaceutics PLC ($LSE:DXRX)
Diaceutics PLC is a diagnostic services company. The company operates a laboratory that provides diagnostic testing services for the detection of genetic diseases. The company also manufactures and sells diagnostic kits and products. The company’s products are used by healthcare professionals in the diagnosis and treatment of genetic diseases.
– Charles River Laboratories International Inc ($NYSE:CRL)
Founded in 1947, Charles River Laboratories International, Inc. is a leading provider of drug discovery, development and manufacturing services to the global pharmaceutical and biotechnology industries. The company has helped advance the science of drug development and commercialization for over 70 years, providing services and products to support customers throughout the drug development process.
Charles River Laboratories International, Inc. has a market cap of $10.47B as of 2022 and a Return on Equity of 13.86%. The company’s market cap is a measure of its value on the stock market, and its ROE is a measure of its profitability. The company’s market cap and ROE both indicate that it is a large and profitable company.
– Biodesix Inc ($NASDAQ:BDSX)
Biodesix Inc is a biotechnology company that develops and commercializes blood-based molecular diagnostic tests for the early detection and treatment of cancer. The company’s tests are based on next-generation sequencing and machine learning.
Biodesix’s market cap is 45.58M as of 2022. The company has a Return on Equity of -655.98%. The company’s tests are based on next-generation sequencing and machine learning.
Summary
Investors in PERSONALIS have seen mixed results in the third quarter of FY2023. Revenue for the quarter was reported at USD 18.2 million, a 22.8% increase from the same period in the prior year.
However, net income for the quarter was reported at -USD 29.1 million, which was worse than the -USD 26.5 million reported in the prior year. The stock price reacted negatively to these results, moving down the same day. Investors should consider all available information when making decisions regarding PERSONALIS.
